Chiba, A. et al. (1997 ) J. Biol. Chem. 272, 2156 polypeptide [Chiba, A. et al. (1997) The phenotypic differences between human DMD and the mouse mdx mutation may result from multiple factors, among which might be the difference in glycosylation patterns on the mouse and human cell surface. Indeed, cell surface glycosylation is highly variable among animal species. Because the cell surface is the site of cellular and molecular recognition events, changes in glycosylation are often linked to disease. In their research, Chandrasekharan et al. have focused on sialic acids, acidic sugars often attached at the nonreducing glycan terminus (i.e., at the outermost portion of the glycan) on the cell surface. The two most abundant sialic acid species in mammals are N-acetylneuraminic acid (Neu5Ac) and N-glycolylneuraminic acid (Neu5Gc), when focused on the modification at C-5 position. Neu5Ac is a precursor of other diverse sialic acids, including Neu5Gc, which is biosynthesized from Neu5Ac at the sugar nucleotide level by a cytosolic reaction catalyzed by CMP-Neu5Ac hydroxylase (Cmah).
While most mammalian species express both Neu5Gc and Neu5Ac, an evolutionary mutation in the CMAH gene has eliminated Neu5Gc expression in humans. The most severe animal model for DMD yet developed is the dystrophindeficient Golden Retriever (Golden Retriever muscular dystrophy; GRMD). Neu5Gc expression in dogʼs skeletal muscle is almost undetectable, suggesting that a lack of Neu5Gc is a major contributing factor to DMD severity in humans.
To create DMD model mice similar to humans in their lack of Neu5Gc, Chandrasekharan et al. developed mdx mice carrying a null mutation in Cmah [Hedlund, M. et al. (2007) Mol. Cell. Biol. 27, 4340 4346] . Compared to mdx mice, the resulting Cmah / mdx mice exhibited much more severe pathogenesis, including early loss of ambulation, weakness of the diaphragmatic and cardiac muscles, and a decrease in life span. Thus in the Cmah / background, mdx mice exhibit a clinical progression and severity of disease more representative of that seen in patients with DMD.
To investigate the molecular mechanism underlying this change in the severity of disease development, Chandrasekharan et al. examined the strength of the DAG complex, focusing on the influence of specific sialic acid species on the binding of α-DG to the ECM proteins laminin and agrin. This binding requires the presence of O-mannosyllinked sialylated tetrasaccharides on a-DG. When α-DG was purified from skeletal muscle of wild-type and Cmah / mice and assessed for its binding to recombinant laminin α2 and 
